Opinion

Video

Timeline of Enfortumab Vedotin in UC: From Previously Treated UC to Frontline Therapy

Author(s):

Thomas Powles MBBS, MRCP, MD

Thomas Powles, MBBS, MRCP, MD, discusses how antibody-drug conjugates have demonstrated improvement over chemotherapy. Data from the EV-301 trial shows that the antibody-drug conjugate enfortumab vedotin decreased the risk of death by 30% versus chemotherapy. Later trial data showed that treatment using enfortumab vedotin plus pembrolizumab (EV+P) reduced the risk of patient death by 53%.

Related Videos
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
2 experts in this video
2 experts in this video
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
4 experts are featured in this series.
Related Content
Cancer | Image Credit: © Cornflakesei - stock.adobe.com
January 10th 2025

Sasanlimab Plus BCG Meets EFS End Point in BCG-Naive, High-Risk NMIBC

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Urothelial Cancer | stock.adobe.com
January 3rd 2025

Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer

Oncology Unplugged
July 24th 2024

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

The OncFive: Top Oncology Articles for the Week of 11/17
November 23rd 2024

The OncFive: Top Oncology Articles for the Week of 11/17

Urothelial Cancer
November 16th 2024

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment